Company / Current Liabilities
Abbott Laboratories Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$16.5B
FY2025
5-year range
$13.1B / $16.5B
FY2021-FY2025
Trend
+16.5%
vs FY2024
Sector context
#9 of 160
Health Care
What the data says
Among 160 Health Care companies, Abbott Laboratories is in the bottom 6% for current liabilities. Increased from $13.8B to $16.5B over the past 2 years.
Based on SEC 10-K filings.
$16.5B in FY2025 with a 5-year CAGR of +6.7%. Top quartile in the Health Care sector.
Increased from $13.8B to $16.5B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +2.1%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 160This company $16.5B Sector average $4.5B
▼
+268.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, current liabilities increased 16.5% year-over-year.
- Ranks #9 out of 160 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.5B | +16.5% |
| FY2024 | $14.2B | +2.3% |
| FY2023 | $13.8B | -10.6% |
| FY2022 | $15.5B | +18.2% |
| FY2021 | $13.1B | +10.1% |
| FY2020 | $11.9B | +9.6% |
| FY2019 | $10.9B | +20.5% |
| FY2018 | $9.0B | +1.1% |
| FY2017 | $8.9B | +33.8% |
| FY2016 | $6.7B | -27.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026